Epizyme discards a failed program for tazemetostat as execs work to get an FDA hold lifted -- shares crater
Epizyme’s woes with its lead program for tazemetostat just got much worse.
The FDA stepped in and slapped a partial hold on their $EPZM lead …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
